54 related articles for article (PubMed ID: 30513220)
1. Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016.
Rutten KHG; Raymakers RAP; Hazenberg BPC; Nienhuis HLA; Vellenga E; Minnema MC
Amyloid; 2018 Dec; 25(4):227-233. PubMed ID: 30513220
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
Oubari S; Hegenbart U; Schoder R; Steinhardt M; Papathanasiou M; Rassaf T; Thimm A; Hagenacker T; Naser E; Duhrsen U; Reinhardt HC; Kortum M; Agis H; Schonland S; Carpinteiro A
Haematologica; 2024 Jan; 109(1):220-230. PubMed ID: 37439344
[TBL] [Abstract][Full Text] [Related]
3. Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.
Ravichandran S; Cohen OC; Law S; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Sachchithanantham S; Mahmood S; Hawkins PN; Wechalekar AD
Blood Cancer J; 2021 Jun; 11(6):118. PubMed ID: 34155191
[TBL] [Abstract][Full Text] [Related]
4. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
[TBL] [Abstract][Full Text] [Related]
5. Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data.
Ravichandran S; Cohen OC; Law S; Sachchithanantham S; Mahmood S; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Hawkins PN; Wechalekar AD
Br J Haematol; 2021 Aug; 194(3):587-597. PubMed ID: 34189728
[TBL] [Abstract][Full Text] [Related]
6. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.
Gustine JN; Staron A; Mendelson L; Joshi T; Gopal DM; Siddiqi OK; Ruberg FL; Sanchorawala V
Blood Adv; 2023 Oct; 7(20):6080-6091. PubMed ID: 37581513
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis.
Cohen OC; Ismael A; Pawarova B; Manwani R; Ravichandran S; Law S; Foard D; Petrie A; Ward S; Douglas B; Martinez-Naharro A; Chacko L; Quarta CC; Mahmood S; Sachchithanantham S; Lachmann HJ; Hawkins PN; Gillmore JD; Fontana M; Falk RH; Whelan CJ; Wechalekar AD
Eur Heart J; 2022 Jan; 43(4):333-341. PubMed ID: 34472567
[TBL] [Abstract][Full Text] [Related]
8. Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients.
Khwaja J; Ravichandran S; Bomsztyk J; Cohen O; Foard D; Martinez-Naharro A; Venneri L; Fontana M; Hawkins PN; Gillmore J; Lachmann HJ; Mahmood S; Whelan C; Kirkwood AA; Wechalekar A
Haematologica; 2024 May; 109(5):1598-1602. PubMed ID: 38205538
[No Abstract] [Full Text] [Related]
9. Prognostic Value of Holter Monitoring in Light Chain Amyloidosis.
Sun Y; Zhao Q; Liu Y; Wen L; Dou X; Lu J; Liu J
J Clin Med; 2023 Dec; 12(23):. PubMed ID: 38068514
[TBL] [Abstract][Full Text] [Related]
10. Grading cardiac response in AL amyloidosis: implications for relapse and survival.
Eckhert E; Witteles R; Kaufman G; Lafayette R; Arai S; Schrier S; O'Shaughnessy M; Liedtke M
Br J Haematol; 2019 Jul; 186(1):144-146. PubMed ID: 30569572
[No Abstract] [Full Text] [Related]
11. Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report.
Chen W; Ren G; Zuo K; Huang X
Medicine (Baltimore); 2018 Dec; 97(50):e13589. PubMed ID: 30558027
[TBL] [Abstract][Full Text] [Related]
12. Decompensated Liver Disease due to Primary Hepatic Amyloidosis: Is Liver Transplantation Still Mandatory?
Riveiro-Barciela M; Gironella M; Senín A; Salcedo MT; Merino-Casabiel X; Castells L; Esteban R; Buti M; Martínez-Valle F
Hepatology; 2019 Jun; 69(6):2701-2703. PubMed ID: 30561765
[No Abstract] [Full Text] [Related]
13. [First-line treatment of multiple myeloma].
Breitkreutz I; Raab M; Goldschmidt H
Internist (Berl); 2019 Jan; 60(1):23-33. PubMed ID: 30552458
[TBL] [Abstract][Full Text] [Related]
14. Kidney embolization induces prompt organ response in a 86-year-old patient with MGRS-related AL-amyloidosis.
Küchlin S; Duffner J; Scheubeck S; Schoeller K; Maruschke L; Seidl M; Engelhardt M; Walz G; Prager EP; Waldschmidt JM
Hemodial Int; 2019 Apr; 23(2):E59-E64. PubMed ID: 30548910
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.
Puig N; Paiva B; Lasa M; Burgos L; Perez JJ; Merino J; Moreno C; Vidriales MB; Toboso DG; Cedena MT; Ocio EM; Lecumberri R; García de Coca A; Labrador J; Gonzalez ME; Palomera L; Gironella M; Cabañas V; Casanova M; Oriol A; Krsnik I; Pérez-Montaña A; de la Rubia J; de la Puerta JE; de Arriba F; Prosper F; Martinez-Lopez J; Lecrevisse Q; Verde J; Mateos MV; Lahuerta JJ; Orfao A; San Miguel JF
Leukemia; 2019 May; 33(5):1256-1267. PubMed ID: 30542145
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of bortezomib-based therapy in myeloma.
Djebbari F; Srinivasan A; Vallance G; Moore S; Kothari J; Ramasamy K
PLoS One; 2018; 13(12):e0208920. PubMed ID: 30540831
[TBL] [Abstract][Full Text] [Related]
17. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome.
Paquin AR; Kumar SK; Buadi FK; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Hwa L; Fonder A; Hobbs M; Hayman SR; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Lin Y; Gonsalves WI; Kourelis T; Warsame R; Kyle RA; Rajkumar SV
Blood Cancer J; 2018 Dec; 8(12):125. PubMed ID: 30538223
[TBL] [Abstract][Full Text] [Related]
18. Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death.
Kim IY; Shim MJ; Lee DM; Lee AR; Kim MA; Yoon MJ; Kwon MR; Lee HI; Seo MJ; Choi YW; Choi KS
Biochem Pharmacol; 2019 Apr; 162():41-54. PubMed ID: 30529689
[TBL] [Abstract][Full Text] [Related]
19. Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.
Sidiqi MH; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Mar; 25(3):e108-e111. PubMed ID: 30529461
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents.
Su B; Zhu X; Jiang Y; Wang L; Zhao N; Ran X; Zheng X; Guo H
Leuk Lymphoma; 2019 Jun; 60(6):1381-1388. PubMed ID: 30516074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
